Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Biphasic Insulin Analogs For Treatment Of Diabetes: A Review

J. Tibaldi
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Diabetes mellitus (DM) is associated with a huge social and economic burden. Achieving guidelines glycemic targets can help reduce the burden of type 2 DM (T2DM)-related complications; however many patients fail to meet these goals. The introduction of insulin analogs, including biphasic insulin analogs, has helped to reduce barriers to patient adherence and to improve outcomes. This review examines the clinical benefits and cost utility of biphasic insulin analogs versus other treatment approaches, in particular human biphasic insulins. Biphasic insulin analogs have a greater flexibility of dosing as compared to equivalent human insulin preparations, resulting in greater convenience and patient satisfaction, and in observational studies, improved efficacy in terms of glycemic control in patients inadequately controlled on human biphasic insulin. Biphasic insulin analogs have shown improved postprandial glucose (PPG) control and a reduced risk of hypoglycemia compared with biphasic human insulin. Treatment with biphasic insulin analogs is cost-effective versus other options in the long term. Biphasic insulin analog treatment of uncontrolled T2DM should be considered an appropriate investment of healthcare resources.
This paper references
Overcoming barriers to insulin replacement.
L. Kuritzky (2009)
10.1111/j.1742-1241.2009.02012.x
Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study
S. Shah (2009)
10.1111/j.1464-5491.2005.01511.x
Twice‐daily pre‐mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes
J. Malone (2005)
10.1016/S0084-3741(08)70011-8
Postprandial Blood Glucose Is a Stronger Predictor of Cardiovascular Events Than Fasting Blood Glucose in Type 2 Diabetes Mellitus, Particularly in Women: Lessons from the San Luigi Gonzaga Diabetes Study
L. Kennedy (2007)
10.1055/S-2006-949655
Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
P. Kann (2006)
10.3111/13696990802589122
Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia
Mohammed Ali (2008)
10.1001/JAMA.285.2.182
Effect of improved glycemic control on health care costs and utilization.
E. Wagner (2001)
Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
N. Raja-Khan (2007)
10.1046/j.1464-5491.2002.00733.x
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients
B. Boehm (2002)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
R. Turner (1998)
10.2337/DIACLIN.24.3.115
Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management
V. J. Briscoe (2006)
10.1111/j.1463-1326.2008.00915.x
Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial
A. Liebl (2009)
10.1111/j.1464-5491.2007.02341.x
Hypoglycaemia in Type 2 diabetes
S. Amiel (2008)
10.1007/s001250050617
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up
M. Hanefeld (1996)
10.1007/s00125-005-0048-8
Patient and provider perceptions of care for diabetes: results of the cross-national DAWN Study
M. Peyrot (2005)
10.1185/030079906X00000
Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting
C. Currie (2005)
10.2337/db09-0618
Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis
P. Reaven (2009)
10.1056/NEJM199309303291401
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.
P. Saenger (1993)
10.2337/dc09-S013
Standards of Medical Care in Diabetes—2009
A. Classification (2009)
10.1111/j.1742-1241.2008.01766.x
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long‐term health economic implications in a Swedish setting
G. Goodall (2008)
10.1185/030079907X253636
Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study
M. Shestakova (2007)
10.2337/dc09-S316
Antioxidant Anti-Inflammatory Treatment in Type 2 Diabetes
A. Ceriello (2009)
Biphasic Insulin Analogs for Treatment of Diabetes : A Review 11 of 12 events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis
JL Chiasson
10.1016/J.CLINTHERA.2006.10.017
A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
S. Schwartz (2006)
10.2337/DIACARE.27.9.2285
A systematic review of adherence with medications for diabetes.
J. Cramer (2004)
10.1186/1475-2840-8-53
Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting
R. Straka (2009)
10.2337/DIACARE.25.5.883
Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
K. Hermansen (2002)
10.1016/S1098-3015(10)65672-0
DB3 DECREASED RATES OF MAJOR HYPOGLYCAEMIC EVENTS LEAD TO IMPROVED LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS BIPHASIC HUMAN INSULIN 30 IN TYPE 2 DIABETIC SUBJECTS IN DANISH, FINNISH, GERMAN, NORWEGIAN, SPANISH, SWEDISH, AND UK SETTINGS
M. Lammert (2004)
10.1001/jama.287.19.2563
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.
S. Genuth (2002)
10.1111/j.1463-1326.2005.00563.x
Attainment of glycaemic goals in type 2 diabetes with once‐, twice‐, or thrice‐daily dosing with biphasic insulin aspart 70/30 (The 1‐2‐3 study)
A. Garber (2006)
10.1136/bmj.321.7258.405
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
I. Stratton (2000)
10.1016/j.pcd.2009.01.003
Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.
R. Ligthelm (2009)
10.4158/EP.15.6.540
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
H. Rodbard (2009)
10.2337/dc09-S321
Early Insulin Use in Type 2 Diabetes
Jean-Louis Chiasson (2009)
10.2337/DIACLIN.27.1.4
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
D. Nathan (2009)
10.1016/j.amjmed.2008.03.022
Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.
A. Rolla (2008)
10.2337/DIACARE.25.3.482
The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes.
G. Nichols (2002)
10.1016/S0168-8227(00)81585-5
Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: A randomized 12-week comparison
P. Home (2000)
A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes
Y. Iwamoto (2003)
10.1111/j.1742-1241.2008.01792.x
When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study
H. Jang (2008)
10.1016/J.METABOL.2006.05.012
Targeting postprandial hyperglycemia.
M. Rendell (2006)
Is glycemic control improving in U.S. adults
TJ Hoerger (2008)
10.2337/DIACARE.28.2.260
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
P. Raskin (2005)
The Diabetes Attitudes, Wishes, and Needs (DAWN) study
MM Funnell (2006)
Slow response to loss of glycemic control in type 2 diabetes mellitus.
J. Brown (2003)
10.1016/S0149-2918(02)85129-3
Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
P. Mcsorley (2002)
10.1111/j.1463-1326.2006.00687.x
Improved glycaemic control of thrice‐daily biphasic insulin aspart compared with twice‐daily biphasic human insulin; a randomized, open‐label trial in patients with type 1 or type 2 diabetes
M. Clements (2008)
10.2337/DIACARE.29.04.06.DC05-0053
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
M. Peyrot (2005)
Trends in A 1 C concentrations among U . S . adults with diagnosed diabetes from 1999 to 2004
TJ Hoerger (2008)
10.1007/BF02877782
Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: A retrospective case series analysis from clinical practice
J. Tibaldi (2007)
10.2337/dc07-1122
Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents
J. Rosenstock (2008)
10.1016/S0149-2918(03)80347-8
Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.
R. Balkrishnan (2003)
10.2337/DIACARE.27.7.1535
The burden of treatment failure in type 2 diabetes.
J. Brown (2004)
10.1056/NEJM200006223422507
Randomized, controlled trials, observational studies, and the hierarchy of research designs.
J. Concato (2000)
10.1001/JAMA.290.4.486
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Jean-Louis Chiasson (2003)
10.1016/S0084-3741(08)79219-9
Economic Costs of Diabetes in the U.S. in 2007
J. Leahy (2008)
10.1016/J.CLINTHERA.2004.12.015
Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
J. Malone (2004)
10.1007/s11606-007-0139-y
Delay Of Insulin Addition To Oral Combination Therapy Despite Inadequate Glycemic Control
G. Nichols (2007)
10.1016/S0195-668X(03)00468-8
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
M. Hanefeld (2004)
10.2337/DIACARE.29.02.06.DC05-1989
Standards of Medical Care in Diabetes: Response to Power
V. Fonseca (2006)
10.1055/S-2006-924424
Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
R. Ligthelm (2006)
10.1111/j.1463-1326.2006.00581.x
Insulin therapy in type 2 diabetes patients failing oral agents: cost‐effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US *
J. Ray (2007)
10.1056/NEJM199309303291401
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus
D. Nathan (1993)
The economic effect of hypoglycemia in a health plan.
A. Heaton (2003)
10.1111/j.1742-1241.2009.02002.x
Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study
P. Valensi (2009)
10.1056/NEJM200006223422506
A comparison of observational studies and randomized, controlled trials
Benson (2000)
10.1161/01.CIR.0000134501.57864.66
Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus
K. Esposito (2004)
Trends in A1C concentrations among U.S. adults with diagnosed diabetes
ES Ford (1999)
10.2337/DIACARE.22.8.1258
Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.
P. Roach (1999)
10.1111/j.1742-1241.2009.02064.x
Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
J. Gumprecht (2009)
The Diabetes Attitudes, Wishes, and Needs (DAWN) study
MM Funnell (2006)
10.2337/DIACARE.25.3.476
Lifetime costs of complications resulting from type 2 diabetes in the U.S.
J. Caro (2002)
10.1111/j.1464-5491.2004.01190.x
Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal
C. Kapitza (2004)
10.4158/EP.13.S1.1
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.
H. Rodbard (2007)
10.1007/s12325-008-0080-4
Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China
J. L. Palmer (2008)
Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care 2009; 32 (Supp 2):S232-236
A Ceriello (2009)
10.1016/J.DIABRES.2004.02.010
Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
M. Warren (2004)
10.2337/DIACARE.28.1.59
Predictors of health care costs in adults with diabetes.
T. Gilmer (2005)
10.1185/03007990903354674
Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT
K. Strojek (2009)
10.1016/S0084-3741(09)79372-2
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
F. Ovalle (2009)
Clinical Practice Guidelines Task Force
AACE Diabetes Mellitu (2007)
10.1097/01.jom.0000161727.03431.3e
Contribution of Hypoglycemia to Medical Care Expenditures and Short-Term Disability in Employees With Diabetes
G. Rhoads (2005)
10.1097/SMJ.0b013e318188898e
Importance of Postprandial Glucose Levels as a Target for Glycemic Control in Type 2 Diabetes
J. Tibaldi (2009)
10.1016/S1056-8727(03)00076-X
Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin.
C. Kilo (2003)
Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004.
Earl S. Ford (2008)
10.1177/0145721705285638
Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes
Jerry D Meece (2006)
10.1016/J.EJIM.2004.10.001
Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes.
B. Boehm (2004)



Semantic Scholar Logo Some data provided by SemanticScholar